Sign In
Buy AVEO
$15.00
+0 (+0%)
At Close: Apr 18, 2023
What Makes AVEO (AVEO) a Good Fit for "Trend Investing"
10:32am, Friday, 26'th Aug 2022
AVEO (AVEO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
A Current Assessment On AVEO Pharmaceuticals
02:25pm, Monday, 15'th Aug 2022
Today, we put small oncology name AVEO Pharmaceuticals in the spotlight for the first time in three and a half years. The company is seeing good sales growth from its franchise drug that was approved
Has AVEO Pharmaceuticals (AVEO) Outpaced Other Medical Stocks This Year?
01:40pm, Friday, 12'th Aug 2022 Zacks Investment Research
Here is how AVEO Pharmaceuticals (AVEO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Has AVEO Pharmaceuticals (AVEO) Outpaced Other Medical Stocks This Year?
11:17am, Friday, 12'th Aug 2022
Here is how AVEO Pharmaceuticals (AVEO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Wall Street Analysts Believe AVEO (AVEO) Could Rally 113%: Here's is How to Trade
01:55pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
The consensus price target hints at an 113.2% upside potential for AVEO (AVEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Recent Price Trend in AVEO (AVEO) is Your Friend, Here's Why
12:50pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
AVEO (AVEO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in AVEO (AVEO) is Your Friend, Here's Why
10:33am, Tuesday, 09'th Aug 2022
AVEO (AVEO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q2 2022 Results - Earnings Call Transcript
10:55pm, Thursday, 04'th Aug 2022
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Hans Vitzthum - LifeSci Advisors Michael Bailey - President & Chief Executive
AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates
10:55pm, Thursday, 04'th Aug 2022 Zacks Investment Research
AVEO (AVEO) delivered earnings and revenue surprises of 11.11% and 2.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for
02:00pm, Monday, 01'st Aug 2022 Zacks Investment Research
Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022
08:05pm, Thursday, 28'th Jul 2022 GlobeNewswire Inc.
BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report second quarter 2022 finan
AVEO Pharmaceuticals Is Primed For A Breakout
12:56pm, Tuesday, 24'th May 2022
AVEO is a mostly forgotten name that is seeing very good growth in their lead product FOTIVDA. Their share price has run lower from exuberant highs reached almost 5 years ago, even as their fundamenta
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
12:30pm, Wednesday, 18'th May 2022 GlobeNewswire Inc.
BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
08:30am, Wednesday, 18'th May 2022
BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will p
AVEO Pharmaceuticals' (AVEO) CEO Michael Bailey on Q1 2022 Results - Earnings Call Transcript
05:57pm, Thursday, 05'th May 2022
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Hans Vitzthum – LifeSci Advisors Michael Bailey – President and Chief Executi
